StreetAlpha.app
Home › Stocks › NAUT

Nautilus Biotechnology, Inc. (NAUT)

Healthcare
$2.12
▼ −2.30%
LAST CLOSE · NOV 20

Nautilus Biotechnology makes the Voyager platform, a system of instruments, consumables and software for measuring proteins in research. It last closed at $2.12 on Nov 20, down 2.30% on the day. The next earnings report for NAUT is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, NAUT reported EPS of -$0.12 on revenue of $234,000. Over its last 8 reports the stock moved an average of 11.9% the session after earnings. Over the last 12 months NAUT insiders bought $65K of stock on the open market and sold $11.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is NAUT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NAUT.

Key Stats

Last 12 months
Results
Net income
−$58.6M
EPS (diluted)
−$0.46
Free cash flow
−$55.1M
Valuation
Market cap
$270.0M
127.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.5M
At Sep 30
Shareholder equity
$116.6M
Shares outstanding
127.4M
At Oct 22
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$50.3M−$50.3MFY2021FY2022: −$57.9M−$57.9MFY2022FY2023: −$63.7M−$63.7MFY2023FY2024: −$70.8M−$70.8MFY2024FY2025: −$59.0M−$59.0MFY2025

From NAUT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
-$0.12
Quarter ended Sep 2026
Year ago EPS
-$0.11
Same quarter last year
Revenue
$234,000
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.14Dec '24Mar 2025: -$0.13Mar '25Jun 2025: -$0.12Jun '25Sep 2025: -$0.11Sep '25Dec 2025: -$0.11Dec '25Mar 2026: -$0.12Mar '26Jun 2026: -$0.11Jun '26Sep 2026: -$0.12Sep '26Latest -$0.12
Revenue by quarter
Jun 2025: $0Jun '25Sep 2025: $0Sep '25Jun 2026: $190,000Jun '26Sep 2026: $234,000Sep '26Latest $234,000
How NAUT moved after its last 8 reports
Average move the session after a report ±11.9%
Oct 26, 2026After the close+18.4%
Jul 27, 2026After the close−27.7%
Apr 28, 2026Before the open+0.8%
Feb 25, 2026After the close−16.3%
Oct 27, 2025After the close+5.9%
Jul 30, 2025After the close0.0%
Apr 28, 2025After the close+8.0%
Feb 26, 2025After the close−18.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NAUTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NAUT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NAUT

Technical Analysis

NAUT · as of the Nov 20 close · updated each morning
Turning down

The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is fading (RSI 46). The nearest support is the swing low (Jun 18) at $2.11, and the nearest resistance the 200 day average at $2.13.

Short trendBearish
Long trendNeutral
MomentumFading
StretchNormal
VolatilityHigh, 15.4%/day
Key levels
$4.3152 week high+103.3%
$2.45Swing high (Jun 25)+15.6%
$2.4420 day average+15.1%
$2.22Pivot R1+4.7%
$2.13200 day average+0.5%
$2.12Last close
$2.11Swing low (Jun 18)−0.5%
$2.06Pivot−2.8%
$2.0050 day average−5.7%
$1.96Pivot S1−7.5%
$1.60100 day average−24.5%
$0.8452 week low−60.4%
Indicators
RSI (14)46.46Middle of its rangeNeutral
MACD0.02Below its signal lineBearish
Stochastic32.4Middle of its rangeNeutral
ADX (14)21.8Weak trend
Williams %R-66.7Oversold below −80, overbought above −20Neutral
CCI (20)-112.5Oversold below −100, overbought above 100Oversold
Rate of change−4.9%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 15.4% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Below
What happened before, for NAUT

What happened before

See how NAUT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NAUT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NAUT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NAUTHow many large options trades hit NAUT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

NAUT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▲46 buying vs 34 selling
  • ▼Held by funds -5.6 pts
  • ▼Funds holding -6
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8894−6.4%
In funds' top 1001−100.0%
Held by funds33.8%39.4%−5.6 pts
New / increased10 / 3631 / 29−23.3%
Reduced / sold out18 / 1611 / 17+21.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NAUT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NAUT Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$65K1 buy · 1 insider
Sold$11.8M1 sale · 1 insider
2026-03 bought $65K2026-06 sold $11.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 2AH Equity Partners Bio II, L.L.C.10% ownerSale5,000,000$2.35$11.8M
Mar 4Sujal M PatelCEO, President, and SecretaryBuy25,000$2.61$65K
Nov 6, 2025Kentaro SuzukiChief Marketing OfficerBuy4,000$1.49$6K
Sep 8, 2025Sujal M PatelCEO, President, and SecretaryBuy200,000$0.67$135K
Sep 4, 2025Matthew B. MurphyGeneral CounselBuy20,000$0.64$13K
May 29, 2025Anna MowryCFO and TreasurerBuy15,000$0.77$12K
Every insider buy and sale for NAUT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NAUT insider trades →

From SEC Form 4 filings by NAUT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAUT is in one of them and how their past NAUT trades turned out.

NAUT in the AI portfolios
Loading…

NAUT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NAUT in an article yet. Here's the latest on the wider market.

NAUT in the news

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company based in Seattle, Washington, that is developing tools for measuring proteins in biological samples. Its Voyager platform combines instruments, consumables and software for proteomics research, with the aim of counting protein and protein variant levels one molecule at a time. The company serves researchers and life science customers. For now it offers analysis services to a limited group of early access customers while it works toward broader commercial sales. Its technology is aimed at drug discovery, biomarker research and precision medicine.

Headquarters
Seattle, WA